Wechselwirkungen · Qdenga
Qdenga powder and solvent for solution for injection Qdenga powder and solvent for solution for injection in pre-filled syringe Dengue tetravalent vaccine (live, attenuated) · Abschnitt 4.5 · PDF-Seite 5
HOS-144698 · Präparat HOS-099244
Qdenga should not be administered to subjects receiving immunosuppressive therapies such as high doses of systemic corticosteroids within 4 weeks prior to vaccination, or any other medicinal product with known immunosuppressive properties including chemotherapy (see section 4.3). The time to avoid vaccination after immunosuppressive treatment should be considered on an individual basis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-04T12:15:00Z · SHA-256 f0e1da92d206a9ab00b8eab81d75d970f8b633f9b7c5ab9ec49d461a2b3745c5 · Passage eefb3a7f13cc48cce6ce05514dfcbb7abc0d6bca4f95147654a80c4f1ea2c02d · Zeichen 404–793 im Abschnitt